BioMimics 3D vascular stent system for femoropopliteal interventions
Two-year results from the real-world multicenter MIMICS-3D registry
Abstract
Summary:Background: The MIMICS-3D study aimed to assess the safety and effectiveness of the BioMimics 3D Vascular Stent System for the treatment of symptomatic femoropopliteal artery disease in a real-world patient population. Patients and methods: Consecutive participants who were scheduled for implantation of the BioMimics 3D stent were enrolled in the prospective, observational, multicenter study. The primary effectiveness outcome was freedom from clinically driven target lesion revascularization at 12 months and the primary safety outcome was a composite of major adverse events comprising death, major target limb amputation, or clinically driven target lesion revascularization at 30 days. Outcomes through 24 months are reported. Results: A total of 507 patients (70±10 years, 65.5% male sex) were enrolled and treated with the study stent. 24.0% had critical limb-threatening ischemia, lesion length was 127±92 mm, and 56.8% of lesions were totally occluded. The Kaplan-Meier (KM) estimate of freedom from clinically driven target lesion revascularization at twelve-months was 90.6% (95% CI: 87.9%–93.3%) and the 30-day primary safety outcome occurred in 1.2% (95% CI: 0.5%–2.7%) of participants. At 24 months, clinical improvement was achieved in 86.6% and the KM estimate of freedom from clinically driven target lesion revascularization was 82.8% (95% CI: 79.4%–86.4%). The KM estimate of freedom from loss of primary patency according to PSVR >2.4 was 78.6% (95% CI: 74.7%–82.4%). Survival distribution functions regarding primary patency were lower with long lesions (>150 mm; log-rank p<0.001) but did not differ significantly between participants with or without critical limb-threatening ischemia (log-rank p=0.07). Conclusions: Endovascular treatment of atherosclerotic femoropopliteal lesions with the BioMimics 3D Vascular Stent System is efficacious and safe in a real-world setting.
References
1 . Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev. 2014;2014(6):CD006767.
2 Clinical outcomes and cost comparisons of stent and non-stent interventions in infrainguinal peripheral artery disease: Insights from the Excellence in Peripheral Artery Disease (XLPAD) registry. J Invasive Cardiol. 2019;31(1):1–9.
3 . Swirling flow and wall shear: evaluating the BioMimics 3D helical centerline stent for the femoropopliteal segment. Int J Vasc Med. 2018;2018:9795174.
4 . Helical centerline stent improves patency: two-year results from the randomized mimics trial. Circ Cardiovasc Interv. 2016;9(6).
5 . Treatment of femoropopliteal lesions with the BioMimics 3D vascular stent system: two-year results from the MIMICS-2 trial. J Endovasc Ther. 2020;1526602820980419.
6 . Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83(6):E212–20.
7 Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: twelve-month results of the SUPERB trial. Circ Cardiovasc Interv. 2015;8(5).
8 The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II). J Vasc Surg. 2013;58(1):73–83.e1.
9 One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY study). J Vasc Surg. 2016;63(2):370–6.e1.
10 S.M.A.R.T. self-expanding nitinol stent for the treatment of atherosclerotic lesions in the superficial femoral artery (STROLL): 1-year outcomes. J Vasc Interv Radiol. 2015;26(1):21–8.
11 Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial. J Endovasc Ther. 2014;21(2):202–12.
12 Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312–5.
13 Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year. Eur J Vasc Endovasc Surg. 2013;46(2):201–12.
14 . Influence of stent fracture on the long-term patency in the femoro-popliteal artery: experience of 4 years. JACC Cardiovasc Interv. 2009;2(7):665–71.
15 Effectiveness of the pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions – the bioflex peace all-comers registry. VASA. 2019;48:425–32.
16 ESVM Guideline on peripheral arterial disease. VASA. 2019;48(Suppl 102):1–79.
17 . Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:158–61.
18 Intimal hyperplasia following implantation of helical-centreline and straight-centreline stents in common carotid arteries in healthy pigs: Influence of intraluminal flow. J R Soc Interface. 2013;10:20130578.
19 . Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282(21):2035–42.
20 Influence of shear stress on in-stent restenosis. In vivo study using 3D reconstruction and computational fluid dynamics. Rev Esp Cardiol. 2006;59(1):20–7.
21 . Reducing in-stent restenosis through novel stent flow field augmentation. Cardiovasc Eng Technol. 2012;3:353–73.
22 . Primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis of randomized controlled trials. J Endovasc Ther. 2012;19:585–95.
23 Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation. Catheter Cardiovasc Interv. 2017;89(7):1250–6.
